Dolores Estrada-Garcia, MD
Hematology & Oncology · Decatur, ILNPI 1316950033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $707, 3.3 times the $212 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 54 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$147
- Merck$107
- Genentech USA, Inc.$100
- Geron Corporation$90
- AbbVie$85
- Lilly USA, LLC$60
- plus $683 from 25 others
What the payments were for
- Speaking & faculty fees$524%
- Food & beverage$1,19694%
- Education$242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $147 |
| Merck | 5 | $107 |
| Genentech USA, Inc. | 1 | $100 |
| Geron Corporation | 1 | $90 |
| AbbVie | 3 | $85 |
| Lilly USA, LLC | 1 | $60 |
| Johnson & Johnson | 1 | $54 |
| Eisai Inc. | 3 | $53 |
| GSK | 3 | $52 |
| Amgen | 3 | $52 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| Bristol Myers Squibb | 2 | $36 |
| AstraZeneca | 2 | $36 |
| Sanofi | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Genmab U.S., Inc. | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Pfizer | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kadcyla$100
How this compares
$1,271 in reported general payments places this provider in the 40th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Decatur
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.